<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309566</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-BEQ-EET-002-V.01</org_study_id>
    <nct_id>NCT03309566</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir</brief_title>
  <official_title>Bioequivalence Study of Efavirenz, Emtricitabine and Tenofovir in Healthy Volunteers, After Administering a Single Dose of a Fixed Dose Combination of the Test Formulation With Respect to the Reference Product, Atripla ® From Gador S.A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorio Elea Phoenix S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorio Elea Phoenix S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence study of two formulations containing a fixed dose combination of 600 mg&#xD;
      Efavirenz, 200 mg Emtricitabine and 300 mg Tenofovir Disproxyl Fumarate in coated tablets&#xD;
      under a single-dose, two-way crossover design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2016</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-dose, two-way crossover.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>192 hours</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>192 hours</time_frame>
    <description>Area under the curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>192 hours</time_frame>
    <description>Drug related toxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test - Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference - Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz, tenofovir disoproxil fumarate and emtricitabine</intervention_name>
    <description>Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.</description>
    <arm_group_label>Reference - Test</arm_group_label>
    <arm_group_label>Test - Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male subjects between 18 and 55 years. Subjects with body mass index (BMI) between 19 and&#xD;
        27 kg / m². Subjects whose complementary tests (ECG, blood and urine) are within normal and&#xD;
        / or clinically insignificant according to the judgment of the investigator.&#xD;
&#xD;
        Subjects with systolic blood pressure between 110 mmHg and 139 mmHg; diastolic pressure&#xD;
        between 70 mmHg and 89 mmHg; heart rate between 50 and 90 beats per minute.&#xD;
&#xD;
        Subjects who signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Background of clinically significant allergies (except untreated asymptomatic seasonal&#xD;
        allergies), drug hypersensitivity and / or hypersensitivity to any component of the&#xD;
        formulations studied.&#xD;
&#xD;
        Drop of more than 20 mmHg in systolic blood pressure or more than 10 mmHg diastolic&#xD;
        pressure in the first 3 minutes of postural change.&#xD;
&#xD;
        Active smoker more than 10 cigarettes / day. Pregnant or lactating women. Current clinical&#xD;
        evidence of severe digestive disorders, surgery of the digestive tract (except&#xD;
        appendectomy).&#xD;
&#xD;
        Current clinical evidence of kidney disease. Current evidence of liver disorders Current&#xD;
        clinical evidence of respiratory and heart diseases. The presence of diabetes mellitus,&#xD;
        thyroid dysfunction or other endocrine disorder.&#xD;
&#xD;
        Evidence of gastroduodenal disease. Current presence of any malignancy. History of abuse or&#xD;
        addiction to drugs or alcohol during the past three years. Participation in a clinical&#xD;
        trial within the last three months. Use of any drug within fourteen days before the start&#xD;
        of the study. Subject donated or suffered blood loss during the last twelve weeks before&#xD;
        the start of the study, or intends to donate blood within three months of the completion of&#xD;
        the study.&#xD;
&#xD;
        Excessive drinking of tea, cocoa, mate, coffee and / or beverages containing caffeine (&gt; 5&#xD;
        cups / day) or wine (&gt; 0.5 L / day) or alcohol (&gt; 50 ml / day).&#xD;
&#xD;
        ECG abnormalities. Positive serology for HIV, hepatitis B or hepatitis C.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María C Fritz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DominguezLab</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DominguezLab</name>
      <address>
        <city>Paraná</city>
        <state>Entre Ríos</state>
        <zip>3102</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

